iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study-Reference-Cited by-同舟云学术

iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study

Published:2022-12-01 Issue:22 Volume:140 Page:2398-2402
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sugimoto Naoshi¹^ORCID,Kanda Junya²^ORCID,Nakamura Sou¹^ORCID,Kitano Toshiyuki²,Hishizawa Masakatsu²,Kondo Tadakazu²^ORCID,Shimizu Shin¹,Shigemasa Akiko¹,Hirai Hideyo³,Arai Yasuyuki³^ORCID,Minami Manabu⁴^ORCID,Tada Harue⁴,Momose Dai⁵,Koh Ki-Ryang⁵,Nogawa Masayuki⁶^ORCID,Watanabe Naohide⁷,Okamoto Shinichiro⁷^ORCID,Handa Makoto⁸,Sawaguchi Akira⁹,Matsuyama Nobuki¹⁰,Tanaka Mitsunobu¹⁰^ORCID,Hayashi Tomoya¹⁰^ORCID,Fuchizaki Akihiro¹⁰^ORCID,Tani Yoshihiko¹⁰,Takaori-Kondo Akifumi²^ORCID,Eto Koji¹^ORCID

Affiliation:

1. 1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

2. 2Department of Hematology, Kyoto University Hospital, Kyoto, Japan

3. 3Department of Clinical Laboratory Medicine, Kyoto University Hospital, Kyoto, Japan

4. 4Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan

5. 5Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan

6. 6Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan

7. 7Division of Hematology, Keio University School of Medicine, Tokyo, Japan

8. 8Center for Transfusion Medicine & Cell Therapy, Keio University School of Medicine, Tokyo, Japan

9. 9Department of Anatomy, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

10. 10Japanese Red Cross Kinki Block Blood Center, Osaka, Japan

Abstract

Refractoriness to platelet transfusion is a major problem in a small group of patients, and large-scale manufacturing of clinical grade functional platelets ex vivo has remained an elusive goal. Sugimoto et al report on the results of the first clinical trial of an autologous transfusion of induced pluripotent stem cell (iPSC)-derived platelets in a patient who had severe aplastic anemia but no compatible platelet donor. Using methodology described in a complementary article in Blood Advances, the results provide proof-of-principle and illustrate the challenges to be faced in taking this approach further.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/140/22/2398/2019187/blood_bld-2022-017296-main.pdf

Reference18 articles.

1. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management;Stanworth;Br J Haematol,2015

2. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells;Nakamura;Cell Stem Cell,2014

3. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production;Ito;Cell,2018

4. Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells;Aihara;Blood Adv,2017

5. Selective inhibition of ADAM17 efficiently mediates glycoprotein Ibα retention during ex vivo generation of human induced pluripotent stem cell-derived platelets;Hirata;Stem Cells Transl Med,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mass production of iPSC-derived platelets toward the clinical application;Regenerative Therapy;2024-03

2. Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics;Platelets;2024-02-05

3. Zelltypen aus menschlichen pluripotenten Zellen und deren Anwendung in Zelltherapien;Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft;2023-12-30

4. Comparative Study of Immunodeficient Rat Strains in Engraftment of Human-Induced Pluripotent Stem Cell-Derived Airway Epithelia;Tissue Engineering Part A;2023-12-20

5. Packaging of supplemented urokinase into naked alpha-granules ofin vitro-grown megakaryocytes for targeted therapeutic delivery;2023-12-05